...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Patient Preference and Adherence >Treatment satisfaction among men with concurrent benign prostatic hyperplasia and erectile dysfunction treated with tadalafil or other phosphodiesterase type-5 inhibitor combinations
【24h】

Treatment satisfaction among men with concurrent benign prostatic hyperplasia and erectile dysfunction treated with tadalafil or other phosphodiesterase type-5 inhibitor combinations

机译：他达拉非或其他磷酸二酯酶5型抑制剂联合治疗对并发良性前列腺增生和勃起功能障碍的男性的治疗满意度

获取原文
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Objective: Erectile dysfunction (ED) and benign prostatic hyperplasia (BPH) frequently co-occur in men aged ≥40, along with lower urinary tract symptoms (LUTS) secondary to BPH. Given little real-world evidence on treatment use or satisfaction with treatment for concurrent BPH/LUTS and/or ED, this study examined medication regimens and differences in satisfaction and health-related quality of life (HRQoL) across regimens among men with concurrent BPH and ED. Methods: A cross-sectional study was conducted using an Internet survey of participants recruited through an online panel. Respondents (N=736) included men (aged ≥40) who self-reported a diagnosis of both ED and BPH with prescription treatment in the past 3 months for both conditions. Treatment satisfaction (eg, convenience and ease of planning) and HRQoL (eg, International Prostate Symptom Score, sleep quality) were self-reported. Generalized linear models examined the association of regimen with treatment satisfaction and HRQoL, adjusting for covariates (eg, age and comorbidities). Results: Final analyses included participants (N=507) using: tadalafil once-daily monotherapy (22%), tadalafil for ED with an alternate BPH therapy (36%), or another phosphodiesterase type-5 inhibitor (PDE5-I) combination (41%). These groups represented the major categories of treatment regimens found in the sample, excluded participants with ambiguous regimens, and were aligned with current standard of care for BPH and ED. Overall, patients reported moderate levels of BPH and a moderate-to-severe degree of ED. Tadalafil monotherapy patients had higher treatment satisfaction scores and greater reported ease of treatment planning and convenience than PDE5-I combination patients. No significant intergroup differences were found on HRQoL. Conclusion: A majority of patients (59%) took tadalafil alone or in combination for BPH/ED treatment. Tadalafil monotherapy patients reported greater treatment satisfaction than patients taking PDE5-I combination therapy. Higher satisfaction for both effectiveness and convenience of once-daily tadalafil may inform both patient and clinician decisions regarding pharmacotherapy regimens.
机译：目的：勃起功能障碍（ED）和良性前列腺增生（BPH）常见于≥40岁的男性，以及继发于BPH的下尿路症状（LUTS）。鉴于几乎没有关于并用BPH / LUTS和/或ED的治疗使用或对治疗的满意度的现实世界证据，本研究研究了并发BPH和ED。方法：使用互联网调查通过在线小组招募的参与者进行横断面研究。受访者（N = 736）包括在过去3个月中针对这两种情况均通过处方治疗自我诊断为ED和BPH的男性（≥40岁）。自我报告了治疗满意度（例如，计划的便利性和简便性）和HRQoL（例如，国际前列腺症状评分，睡眠质量）。广义线性模型检查了方案与治疗满意度和HRQoL的关联，并调整了协变量（例如年龄和合并症）。结果：最终分析包括使用以下药物的参与者（N = 507）：他达拉非每日一次单药治疗（22％），他达拉非用于ED替代BPH疗法（36％）或另一种磷酸二酯酶5型抑制剂（PDE5-I）组合（ 41％）。这些组代表了样本中发现的治疗方案的主要类别，排除了模棱两可的治疗方案的参与者，并与当前BPH和ED的护理标准保持一致。总体而言，患者报告中度BPH和中度至重度ED。他达拉非单药治疗患者比PDE5-I联合治疗患者具有更高的治疗满意度评分，以及更大的治疗计划便捷性和便利性。在HRQoL上未发现明显的组间差异。结论：大多数患者（59％）单独或联合使用他达拉非用于BPH / ED治疗。他达拉非单药治疗的患者比接受PDE5-I联合治疗的患者满意度更高。每天服用他达拉非对有效性和便利性的更高满意度可能会为患者和临床医生有关药物治疗方案的决策提供依据。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号